Squarepoint’s Immunocore IMCR Stock Holding History

Squarepoint’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$465K	Buy	15,434 +46	+0.3%	+$1.49K	﹤0.01%	3377
2025 Q4	$534K	Buy	+15,388	New	+$543K	﹤0.01%	3160
2025 Q3	–	Sell	-10,714	Closed	-$336K	–	4639
2025 Q2	$336K	Buy	+10,714	New	+$333K	﹤0.01%	3601
2025 Q1	–	Sell	-69,954	Closed	-$2.06M	–	4973
2024 Q4	$2.06M	Sell	69,954 -2,114	-3%	-$66.8K	﹤0.01%	2384
2024 Q3	$2.24M	Sell	72,068 -1,698	-2%	-$61.8K	﹤0.01%	1988
2024 Q2	$2.5M	Buy	73,766 +70,648	+2,266%	+$3.6M	﹤0.01%	1875
2024 Q1	$203K	Buy	+3,118	New	+$214K	﹤0.01%	3614
2023 Q4	–	Sell	-4,738	Closed	-$246K	–	4232
2023 Q3	$246K	Sell	4,738 -1,528	-24%	-$90.4K	﹤0.01%	3287
2023 Q2	$376K	Sell	6,266 -12,764	-67%	-$729K	﹤0.01%	2823
2023 Q1	$941K	Buy	19,030 +5,696	+43%	+$320K	﹤0.01%	1940
2022 Q4	$761K	Buy	13,334 +7,734	+138%	+$435K	﹤0.01%	2021
2022 Q3	$263K	Buy	+5,600	New	+$267K	﹤0.01%	2556

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Squarepoint's IMCR Position: Q1 2026 in Review

Squarepoint increased its Immunocore (IMCR) stake by 0.3% in Q1 2026, buying an estimated $1.49K and bringing the position to 15,434 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

Squarepoint first reported a position in IMCR in Q3 2022 and has held it in 12 quarters since. The position peaked at $2.5M in Q2 2024. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

Squarepoint held 15,434 shares of Immunocore worth $465K as of Q1 2026.
Squarepoint bought 46 Immunocore shares in Q1 2026, an estimated $1.49K.
Immunocore made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3377 holding.
Squarepoint first reported a position in Immunocore in Q3 2022 and has held it in 12 quarters since.
Squarepoint's Immunocore position peaked at $2.5M in Q2 2024.
142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.